FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2552528707> ?p ?o ?g. }

• W2552528707 endingPage "5084" @default.
• W2552528707 startingPage "5084" @default.
• W2552528707 abstract "Abstract INTRODUCTION. Hairy cell leukemia (HCL) is a rare indolent B-cell malignancy, mainly characterized by peripheral cytopenias and splenomegaly. The current standard of treatment for HCL are Nucleoside Analogs (NA) cladribine and pentostatin, which produce remarkably high remission rates and durable responses. Aim of this study was to evaluate efficacy, short- and long-term toxicity of NA in HCL pts treated outside clinical trials. PATIENTS AND METHODS. We retrospectively analyzed 86 HCL patients (pts) treated with NA between 1996 and 2015 in two Hematologic Centers in Italy. The study was conducted in accordance to the Helsinki Declaration of 1964, as revised in 2000. Cladribine and pentostatin were administered according to standard schedules. Response criteria published by Jones et al. (Br J Haematol 2012) were retrospectively applied. Molecular assessment of BRAF-V600E mutation before and after NA therapy using quantitative real-time polymerase chain reaction (qRT-PCR)-based allelic discrimination assay (sensitivity 0.1%) was performed in 10 pts. RESULTS. The median follow-up of pts (71 males and 15 females, median age 53 years) was 5.8 years (range 0.5-28). During the disease course, 86 pts were treated with NA (cladribine n=76, 88%; pentostatin n=10, 12%); 59 pts received NA front-line (cladribine in 56/59 pts, 95%). Among the other 27 pts, receiving NA as second or subsequent line of therapy, 25 had been previously treated with interferon. Median time from diagnosis to the first NA was 3.3 months (range 0-315). Hematological toxicity was observed in 53 of 77 evaluable pts (69%), and was not significantly different with cladribine (72%) or with pentostatin (37%) (p=0.1). Grade 3-4 neutropenia, anemia and thrombocytopenia were observed in 50 (65%), 7 (9%) and 7 (9%) pts respectively. Extra-hematological toxicity was reported in 48 of 79 evaluable pts (61%). The incidence of extra-hematological toxicity with cladribine (63%) and pentostatin (37%) was not statistically different (p=0.2). Grade 3-4 febrile neutropenia was observed in 24 pts (30%); 9 pts (11%) had grade 3-4 infections; 4 pts (5%) had grade 3-4 skin toxicity, 1 pt (1%) had grade 3 hepatic toxicity. Four of 86 pts (5%) developed a second malignancy (prostatic adenocarcinoma n=2, colon adenocarcinoma n=1, diffuse large B cell lymphoma n=1). The median time from NA to second malignancy was 58 months (range 49-111). Four of 86 pts (5%) developed a skin cancer (basal-cell carcinoma n=3, squamous cell carcinoma n=1), after a median time of 59 months (range 16-126). Response was assessed at a median time of 3 months after the end of therapy. Overall Response Rate (ORR) and Complete Remission (CR) Rate were respectively 93% and 63% in the entire cohort, and 98% and 72% in pts treated with NA front-line. The allelic burden of BRAF before and after therapy with NA was available in 10 cases; none of the pts in clinical CR after NA achieved a complete molecular response (Table 1). The median Progression-Free Survival (PFS) for pts treated with NA frontline was 6.5 years. There was a trend toward a longer PFS in pts receiving NA as first-line therapy as compared to those treated in second or subsequent lines (p=0.05). PFS curves according to type of NA and line of therapy are shown in Figure 1. The 5- and 10-year Overall Survival (OS) rates were 96% (95% CI: 85% - 99%) and 90% (95% CI 76%-96%) respectively. OS was similar in pts treated with cladribine orpentostatin (p=0.49). CONCLUSIONS. This study shows that: i) NA are associated with an acceptable toxicity, neutropenia and febrile neutropenia being the main complications of therapy; ii) timing of response assessment may account for a CR rate that is slightly lower than reported in the literature, confirming the importance of waiting at least 4 months for response evaluation as recommended by current guidelines; iii) the persistence of molecular disease also in pts achieving a clinical CR supports the implementation of consolidation strategies aimed at eradicating minimal residual disease to prolong disease-free survival. Table 1. BRAF allelic burden before and after therapy Patient Age (years) Sex Line of Therapy Allelic Burden (%) Clinical Response Pre- Post- 1 33 F 1 21,8 0,1 CR 2 36 M 2 5,4 0,4 CR 3 39 M 1 24,2 0,7 CR 4 54 M 1 10,8 0,3 PR 5 42 F 1 44 1,2 CR 6 53 F 1 7,9 0,2 NV 7 56 M 1 6,5 0,3 CR 8 54 M 1 12,2 0,2 CR 9 32 M 1 35,8 9,5 PR 10 38 M 2 54,4 12,2 PR Figure 1. Progression-free survival according to type of NA and line of therapy Figure 1. Progression-free survival according to type of NA and line of therapy Disclosures Arcaini: Gilead: Consultancy, Other: Advisory Board; Celgene: Consultancy, Other: Advisory Board; Roche: Consultancy, Other: Advisory Board." @default.
• W2552528707 created "2016-11-30" @default.
• W2552528707 creator A5008054206 @default.
• W2552528707 creator A5009436567 @default.
• W2552528707 creator A5019034145 @default.
• W2552528707 creator A5022552300 @default.
• W2552528707 creator A5025215179 @default.
• W2552528707 creator A5037134492 @default.
• W2552528707 creator A5050011235 @default.
• W2552528707 creator A5062221935 @default.
• W2552528707 creator A5068303286 @default.
• W2552528707 creator A5073446288 @default.
• W2552528707 creator A5078369255 @default.
• W2552528707 date "2015-12-03" @default.
• W2552528707 modified "2023-09-27" @default.
• W2552528707 title "Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials" @default.
• W2552528707 doi "https://doi.org/10.1182/blood.v126.23.5084.5084" @default.
• W2552528707 hasPublicationYear "2015" @default.
• W2552528707 type Work @default.
• W2552528707 sameAs 2552528707 @default.
• W2552528707 citedByCount "0" @default.
• W2552528707 crossrefType "journal-article" @default.
• W2552528707 hasAuthorship W2552528707A5008054206 @default.
• W2552528707 hasAuthorship W2552528707A5009436567 @default.
• W2552528707 hasAuthorship W2552528707A5019034145 @default.
• W2552528707 hasAuthorship W2552528707A5022552300 @default.
• W2552528707 hasAuthorship W2552528707A5025215179 @default.
• W2552528707 hasAuthorship W2552528707A5037134492 @default.
• W2552528707 hasAuthorship W2552528707A5050011235 @default.
• W2552528707 hasAuthorship W2552528707A5062221935 @default.
• W2552528707 hasAuthorship W2552528707A5068303286 @default.
• W2552528707 hasAuthorship W2552528707A5073446288 @default.
• W2552528707 hasAuthorship W2552528707A5078369255 @default.
• W2552528707 hasBestOaLocation W25525287071 @default.
• W2552528707 hasConcept C126322002 @default.
• W2552528707 hasConcept C141071460 @default.
• W2552528707 hasConcept C185592680 @default.
• W2552528707 hasConcept C2775952470 @default.
• W2552528707 hasConcept C2776543447 @default.
• W2552528707 hasConcept C2777063308 @default.
• W2552528707 hasConcept C2777333352 @default.
• W2552528707 hasConcept C2778461978 @default.
• W2552528707 hasConcept C2779200787 @default.
• W2552528707 hasConcept C2779338263 @default.
• W2552528707 hasConcept C2780483514 @default.
• W2552528707 hasConcept C2780653079 @default.
• W2552528707 hasConcept C29730261 @default.
• W2552528707 hasConcept C71240020 @default.
• W2552528707 hasConcept C71924100 @default.
• W2552528707 hasConcept C90924648 @default.
• W2552528707 hasConceptScore W2552528707C126322002 @default.
• W2552528707 hasConceptScore W2552528707C141071460 @default.
• W2552528707 hasConceptScore W2552528707C185592680 @default.
• W2552528707 hasConceptScore W2552528707C2775952470 @default.
• W2552528707 hasConceptScore W2552528707C2776543447 @default.
• W2552528707 hasConceptScore W2552528707C2777063308 @default.
• W2552528707 hasConceptScore W2552528707C2777333352 @default.
• W2552528707 hasConceptScore W2552528707C2778461978 @default.
• W2552528707 hasConceptScore W2552528707C2779200787 @default.
• W2552528707 hasConceptScore W2552528707C2779338263 @default.
• W2552528707 hasConceptScore W2552528707C2780483514 @default.
• W2552528707 hasConceptScore W2552528707C2780653079 @default.
• W2552528707 hasConceptScore W2552528707C29730261 @default.
• W2552528707 hasConceptScore W2552528707C71240020 @default.
• W2552528707 hasConceptScore W2552528707C71924100 @default.
• W2552528707 hasConceptScore W2552528707C90924648 @default.
• W2552528707 hasIssue "23" @default.
• W2552528707 hasLocation W25525287071 @default.
• W2552528707 hasOpenAccess W2552528707 @default.
• W2552528707 hasPrimaryLocation W25525287071 @default.
• W2552528707 hasRelatedWork W1891896135 @default.
• W2552528707 hasRelatedWork W1987154737 @default.
• W2552528707 hasRelatedWork W1998497846 @default.
• W2552528707 hasRelatedWork W2033216659 @default.
• W2552528707 hasRelatedWork W2039235314 @default.
• W2552528707 hasRelatedWork W2040184883 @default.
• W2552528707 hasRelatedWork W2394675987 @default.
• W2552528707 hasRelatedWork W2439278013 @default.
• W2552528707 hasRelatedWork W2740129947 @default.
• W2552528707 hasRelatedWork W3210553339 @default.
• W2552528707 hasVolume "126" @default.
• W2552528707 isParatext "false" @default.
• W2552528707 isRetracted "false" @default.
• W2552528707 magId "2552528707" @default.
• W2552528707 workType "article" @default.